Tango Therapeutics will report Q4 2025 results on March 5, 2026, with consensus revenue of $0.50 million and expected EPS of -$0.33. Investors will watch full-year guidance and cash burn metrics for signs of funding runway and clinical progress.

Over the past 90 days, full-year 2025 revenue estimates dipped from $63.02 million to $62.89 million, while 2026 revenue forecasts fell from $16.57 million to $11.23 million. Earnings estimates for 2025 improved slightly from -$0.97 to -$0.93 per share, but 2026 EPS projections were lowered from -$1.25 to -$1.27.

In Q3 2025, Tango delivered $53.81 million in revenue, beating the $37.14 million consensus by 44.9%, and reported EPS of $0.14 versus expectations of -$0.05. The stock reaction was muted, remaining flat the following day despite the sizable upside surprise.

Nine analysts set a one-year average price target of $14.89, implying roughly 29.6% upside, with a high of $19.00 and low of $12.00. Brokerage consensus stands at an Outperform rating (1.6), while a proprietary model values the stock at $1.83, suggesting significant downside risk.